Evidence map›Paper›PMID 42465947›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Standardized, repeatable ulcerative colitis histology scoring and endpoint assessment using an automated, foundation model-based tool.

Waleed Tahir, John Shamshoian, John Tauber, Lani K Clinton, Michael Griffin, Chintan Shah, Geetika Singh, Darren Fahy, Kathleen Sucipto, Jacqueline A Brosnan-Cashman and 27 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors.

Waleed TahirPathAI Inc, Boston, MA.
John ShamshoianPathAI Inc, Boston, MA.
John TauberPathAI Inc, Boston, MA.
Lani K ClintonPathAI Inc, Boston, MA.
Michael GriffinPathAI Inc, Boston, MA.
Chintan ShahPathAI Inc, Boston, MA.
Geetika SinghPathAI Inc, Boston, MA.
Darren FahyPathAI Inc, Boston, MA.
Kathleen SuciptoPathAI Inc, Boston, MA.
Jacqueline A Brosnan-CashmanPathAI Inc, Boston, MA.
Tara A AltepeterUS Food and Drug Administration, Silver Spring, MD.
Sabyasachi BhattacharyaAbbVie Bay Area, South San Francisco, CA.
Wallace CrandallEli Lilly and Company, Indianapolis, IN.
Chong DuanPfizer Research Technology Center, Cambridge, MA.
Jeremy D GalePfizer Research Technology Center, Cambridge, MA.
Vandana GuptaTakeda Pharmaceuticals America Inc, Cambridge, MA, United States.
Hélène HaarmannTakeda Pharmaceuticals International, Opfikon, ZH, Switzerland.
Noam HarpazIcahn School of Medicine at Mount Sinai, New York, NY.
Andrea HooperRegeneron Pharmaceuticals Inc, Tarrytown, NY.
Julie HorowitzRegeneron Pharmaceuticals Inc, Tarrytown, NY.
Andres Hurtado-LorenzoCrohn's and Colitis Foundation, New York, NY.
Bader E HussainiTakeda Pharmaceuticals America Inc, Cambridge, MA, United States.
Vipul JairathWestern University Faculty of Health Sciences, London, ON, Canada.
Autumn JonesFoundation for the National Institutes of Health, North Bethesda, MD.
Ben KostiukCrohn's and Colitis Foundation, New York, NY.
F Stephen LarouxAbbVie Bioresearch Center, Worcester, MA.
Trevor LissoosEli Lilly and Company, Indianapolis, IN.
Russell B McBrideIcahn School of Medicine at Mount Sinai, New York, NY.
Fedaa NajdawiVanderbilt University Medical Center, Nashville, TN.
Anil NayyarUS Food and Drug Administration, Silver Spring, MD.
Mark T OstermanBristol Myers Squibb, Princeton, NJ.
Pratik PanchalTakeda Pharmaceuticals America Inc, Cambridge, MA, United States.
Darren RuaneJanssen Research & Development, Raritan, NJ.ORCID 0000-0002-1053-2313
Paresh ThakkerTakeda Pharmaceuticals America Inc, Cambridge, MA, United States.
Simon P TravisUniversity of Oxford Nuffield Department of Medicine, Oxford, England, United Kingdom.
Laura WilsonKenneth Rainin Foundation, Oakland, CA.
Christina JaysonPathAI Inc, Boston, MA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In clinical trials for ulcerative colitis (UC), pathologists assess disease severity through standardized histological indices, including the Geboes Score, Robarts Histopathology Index (RHI), and Nancy Histologic Index (NHI). Despite strong associations with clinical outcomes, histologic scoring suffers from inter- and intra-reader variability, and consensus criteria for histologic remission remain uncertain. Through a consortium approach, we developed an artificial intelligence-based measurement (AIM) tool for scoring histology in UC mucosal biopsies (AIM-HI UC). This model, trained on a large dataset of UC biopsies (N=10,230), utilizes additive multiple instance learning models leveraging PLUTO, a pathology foundation model, that predict each of the Geboes subgrades, from which the Geboes grade-level score, RHI, and NHI can be calculated. Evaluation of this model on a standalone verification set including clinical trial specimens established algorithm non-inferiority and/or superiority relative to standard qualified pathologists through comparison of algorithm-consensus and pathologist-consensus agreement metrics (non-inferior if difference >-0.1, superior if difference >0, inclusive of confidence intervals). AIM-HI UC was determined to be non-inferior to pathologists (N=3) for the prediction of all seven Geboes subgrades, grade-level Geboes, RHI, NHI, histologic improvement (GS≤3.1), 2A histologic remission (GS<2A.0), and 2B histologic remission (GS<2B.0). AIM-HI UC was superior to pathologists for several Geboes subgrades (GS 0, GS 1, GS 2B, and GS 5), as well as grade-level Geboes, RHI, and positive percent agreement of 2A histologic remission. The model was shown to be greater than 99% repeatable for all histologic scoring metrics examined. Model-derived scores were shown to strongly correlate with canonical histologic features of inflammation, including the proportion of total epithelium that is inflamed (Spearman r=0.83; p<0.01), the proportion of neutrophils localized within crypt epithelium (Spearman r=0.83, p<0.01), and the amount of mucosal area classified as erosion or ulceration (Spearman r=0.80, p<0.01). Overall, these results suggest that AIM-HI UC has the potential to improve consistency of UC histology interpretation, providing a path toward standardization of UC histology scoring in clinical trials.

Identifiers

PMID42465947
PMCPMC13370600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.